From: Cancer Drug Discovery and Development: Death Receptors in Cancer Therapy Edited by: W. S. El-Deiry © Humana Press Inc., Totowa, NJ
263
15 TRAIL in Cancer Therapy
Mahaveer Swaroop Bhojani, P h D , Brian D. Ross, P h D ,
and Alnawaz Rehemtulla, P h D
SUMMARY
Death receptors and their ligands have recently garnered much attention for therapeu- tic intervention of tumor progression. In clinical oncology, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors are the most prominent duos in the death-receptor-ligand guild for their ability to specifically eliminate cancer cells without any deleterious effect on normal cells. Although in recent years five TRAIL receptors have been identified and a number of checkpoints involved in the TRAIL pathway are known, a well defined signaling pathway remains elusive and appears to be very com- plex. In spite of TRAIL possessing a high therapeutic index, some tumor cells evade TRAIL-mediated cell death by utilizing a plethora of different regulators, such as cellular FLICE- inhibitory protein (c-FLIP), caspase-8, NF-gB, Akt, and/or decoy receptors, which either stall or shunt death signaling by mechanisms that remain poorly understood.
Interestingly, a number of recent reports suggest that a key to the success of TRAIL in cancer therapy is to use it in conjunction with chemo- or radiotherapy. Such a concept of combination therapy is gaining ground in eliminating tumors that are refractory to treat- ment with TRAIL, ionizing radiation, or chemotherapeutic agents alone. Results from preclinical studies on TRAIL have been very promising for cancer treatment; however, outcome from phase I/II clinical trials is eagerly awaited to assess its safety. Time will show whether TRAIL will be the foremost weapon in the clinical oncologist’s arsenal to eradicate tumors.
DEATH RECEPTORS AND THEIR LIGANDS
Apoptosis is a genetically regulated physiological form of cell death that plays an important role in the removal of unwanted cells from most multicellular organisms (1).
It occurs in a variety of physiological processes, including embryonic development,
tissue remodeling, immune regulation, and tumor regression, and in a variety pathologi-
cal states, which include tumor growth, myocardial infarction, and neurodegenerative
disorders (2). Such forms of cell death culminate in a characteristic cellular morphology,
which includes compaction of the cell, chromatin condensation, internucleosomal DNA degradation, membrane blebbing, and fragmentation of the cell into the apoptotic bodies (1) These key morphological alterations are brought about by activation of a family of intracellular proteases, collectively known as caspases—cysteine proteases with speci- ficity for aspartic acid residues (3). In the active state, caspases are dimeric and composed of two identical large subunits and two identical small subunits (4). Targets for execu- tioner caspases include various key cellular substrates, which when degraded signal the demise of the cells. It is interesting that a variety of different stimuli culminate in the activation of the same executioner caspases. These stimuli include environmental stress, cytotoxic agents, absence of growth factors, and activation of death receptors upon binding of their ligands.
The death receptors, as the name suggests, are cell-surface proteins with the potential to transmit a death message generated on the outside of the cell, by the binding of the death ligands to the apoptotic signaling machinery located inside the cell. There are seven known human death receptors: Fas (Apo-1, CD95), tumor necrosis factor receptor (TNFR)1 (p55-TNFR, CD120a), death receptor (DR)3 (WSL-1, APo-3, TRAMP, LARD), DR4 (TRAIL-R1), DR5 (TRAIL-R2, TRICK-2, KILLER), DR6, and EDA-R;
each harbors a death domain (DD) at the cytoplasmic tail that couples the receptor to the caspase cascade essential for the induction of apoptosis (5) (see also Fig. 1). All known death receptors belong to the TNFR superfamily, and their ligands to the tumor necrosis factor (TNF) superfamily. Although Fas signaling remains the most extensively scruti- nized death receptor signaling pathway, where the molecular mechanisms seem to be completely elucidated (reviewed in refs. 5–7), investigating TRAIL and transduction of apoptotic signal by its cognate death receptors has been the most exciting exploration in oncology, since TRAIL possesses unique cytotoxic capability directed against a wide range of tumor cells but not normal cells (5).
TRAIL and Its Receptors
TRAIL was discovered using a bioinformatics approach, where an expressed sequence tag database was screened for a characteristic TNF sequence motif, which lead to cloning of full-length TRAIL cDNA. Since it had sequence homology to the FAS/APO1 ligand (23% identity) and TNF (19% identity), the newly discovered protein was named APO2 ligand (APO2L) or TRAIL (8,9). Investigation of TRAIL function revealed that it induces cell death in a wide variety of transformed cell lines, even those that were inherently resistant to high levels of chemotherapeutic drugs (5,8,9). TRAIL is a type II transmem- brane protein with a metalloprotease-susceptible exposed carboxyterminal region lying on the extracellular space (10). Recombinant soluble TRAIL, which constitutes the extracel- lular portion, was sufficient for exerting its cytotoxic effect (8,9,11,12). The biologically active form of TRAIL is a trimer that is stabilized by a zinc ion interacting with a cysteine residue at position 230 of each subunit (13–15).
TRAIL induces apoptosis within the target cell by interacting with specific cell-sur- face receptors (Fig. 1). To date, five receptors that can bind TRAIL have been identified.
Death receptor-4 (DR4, TRAIL-R1) and death receptor-5 (DR5, KILLER,TRAIL-
R2,TRICK2) are type I transmembrane proteins containing two cysteine-rich extracel-
lular ligand-binding domains and a cytoplasmic death domain, a region of approx 80
amino acids required for transmitting a cytotoxic signal (16–21). In contrast, the other
Fig. 1. Death receptors and their cognate ligands. The transmembrane ligands are labeled at top.
The death receptors are the darker shaded ovals. Small circles and pentagons stand for the cysteine- rich domains and cytoplasmic death domains respectively. Arrows with solid lines symbolize strong binding, while dashed lines correspond to low-affinity binding between ligand and cognate receptor. The cognate ligand of DR6 is yet to be identified.
three receptors do not have a functional death domain and may act as decoy receptors (16,17,19,20). Decoy receptor-1 (DcR1, TRID, TRAIL-R3), which lacks a death domain, and decoy receptor-2 (DcR2, TRUNDD, TRAIL-R4), which contains a truncated death domain, do not transduce apoptogenic signals. However, both decoy receptors (DcR1 and DcR2) and death receptors (DR4 and DR5) possess comparable affinity for binding to TRAIL. The third decoy receptor, osteoprotegerin (OPG), which was initially identi- fied as a receptor for RANKL/OPGL, is a weak soluble receptor for TRAIL. Biological significance of OPG as a receptor for TRAIL remains to be elucidated (22).
TRAIL and Apoptosis
The key feature of cell-death signaling is the activation of caspases, which may be achieved through two principle routes—the extrinsic and intrinsic death pathways (Fig. 2 and refs. 4,5). Death receptors use the extrinsic signaling pathway to convey the death cues to the cells, while the chemotherapeutic agents trigger the intrinsic pathway to apoptosis (5). Increasing evidence suggests a cross-talk between the two pathways (see Fig. 2, next section, and the section on combination therapy).
T
HEE
XTRINSICP
ATHWAYThe cell-extrinsic pathway utilizes the engagement of cell-surface death receptors by
their ligands in initiating apoptosis (5,23). Upon ligation of death receptors by their
respective ligands, adaptor proteins such as FADD are recruited to the cytoplasmic tail
Fig. 2. Apoptotic pathway. Caspase activation and subsequent induction of apoptosis occur by two major pathways: the extrinsic and the intrinsic pathway. See text for further details.
of the receptor, which in turn recruit procaspases 8 and 10, leading to the assembly of the death-inducing signaling complex (DISC) (24–26). By virtue of being brought into prox- imity with one another, procaspases 8 and 10 autocatalytically bring about their own activation (3). Once active, these caspases consecutively activate the same set of execu- tioner caspases (caspase-3, -6, and -7) that are activated by caspase-9 via the cell-intrinsic pathway (5). This apoptogenic caspase machinery triggered by the cell-extrinsic pathway is independent of p53 status and is unaffected by Bcl-2 or Bcl-xL (23). The prime negative regulator of TRAIL-induced apoptosis may be c-FLIP, which prevents apoptosis by blocking the assembly of DISC (27–29,79).
T
HEI
NTRINSICP
ATHWAYThe other route to activation of cell death is the cell-intrinsic, or mitochondrial, path- way (Fig. 2). This pathway is activated by cytotoxic agents, severe cell distress akin to DNA damage, defective cell cycle, detachment from the extracellular matrix, hypoxia, and loss of survival factors (30). This pathway is triggered by the pro-apoptotic members of the BCL2 superfamily, initially by a subset called the “BH3-only subfamily,” which includes Bid, Bim, Harikari, and Noxa (23,31). These proteins engage another set of proapoptotic Bcl-2 members, the Bax subfamily (which includes Bax, Bak, and probably Bok), loosely residing on the mitochondrial outer membranes or in the cytosol (23).
This interaction causes the latter to oligomerize and insert into the mitochondrial membrane, resulting in release of the key apoptogenic factors cytochrome c and Smac/
DIABLO (32,33). Within the cytosol, cytochrome c binds the adaptor APAF1, forming an apoptosome that recruits and activates the apoptosis-initiating protease caspase-9 (34). Functional caspase-9 sets the momentum for activation of the executioner proteases caspase-3, -6, and -7 (3). On the other hand, Smac/DIABLO exerts its role in supplement- ing apoptosis by binding to inhibitors of apoptosis (IAPs) and thereby preventing IAPs from attenuating caspase activation (32,33,35). Funtional p53 appears to be a general requirement for engaging this death pathway (23). DNA damage caused by most chemo- and radiotherapy triggers apoptosis in tumor cells by activating the intrinsic pathway.
However, cells harboring non-functional p53 continue to proliferate and sidestep apoptosis, despite genotoxic stress induced by chemotherapy or irradiation (23).
T
HEC
ROSS-T
ALKGrowing evidence suggests that the drug-induced intrinsic pathway and the death receptor-activated extrinsic pathway overlap during activation of cell death, and such convergence may be either at sharing of death receptors, caspase signaling cascade, upstream or downstream of mitochondrial signaling, or at the level of p53 or NF-gB signaling (5,36). For example, certain DNA-damaging agents may activate both apoptotic pathways, such that blocking of either receptor pathway by overexpression of dominant- negative FADD or of the mitochondrial pathway by Bcl-xL only partially inhibited apoptosis (37). Death receptors activate the cell-intrinsic pathway by caspase-8-medi- ated cleavage of BID, which interacts with BAX and BAK to induce release of cyto- chrome c and Smac/DIABLO, leading to increased activation of caspase-9 and -3 (Fig. 2 and ref. 38). Additionally, transcriptional upregulation of Fas and DR5 is reported to occur in response to DNA damage, via either a p53-independent or -dependent pathway (39).
Up-regulation increases the sensitivity of death receptor signals to their ligands. Further-
more, mismatch-repair-deficient tumors can acquire resistance to TRAIL by mutational
inactivation of BAX, and such cells may be sensitized to TRAIL by pre-exposure to chemotherapeutic agents that lead to up-regulation of DR5 and BAK (40). Thus the different death stimuli based on the target cell may use either of the signaling pathways or both, and such understanding is of immense importance in developing rationally designed therapy for human malignancies.
Biological Role of TRAIL and Its Receptors
The physiological function of TRAIL remains to be understood, but its main biological activity appears to be induction of apoptosis. TRAIL gene-knockout mice were more susceptible to experimental and spontaneous tumor metastasis, indicating that TRAIL has a crucial physiological role in antitumor surveillance by immune cells (41). Alter- nately, experiments with mice in which the TRAIL activity was blocked by administra- tion of neutralizing antibodies, incriminate TRAIL in interferon a-dependent suppression of tumors by NK cells (42). This is further corroborated by the observation that not only do activated NK cells, monocytes, and CD4
+or CD8
+T-cells express TRAIL, but they use it to trigger apoptosis in tumor targets (43–50). TRAIL has been implicated in apoptogenic activity of type I interferon in renal cell carcinoma and multiple myleomas (51,52). Furthermore, up-regulation of TRAIL is observed when cells are infected with reovirus or herpes virus, suggesting that virus-infected cells are eliminated using the TRAIL pathway (53,54). These results suggest an important yet partially understood role for TRAIL in immune surveillance (suppressing tumor initiation, progression, and viral propagation).
TRAIL AND CANCER THERAPY
Most of the excitement with TRAIL as a promising therapeutic agent for treatment of malignancies is due to its ability to exert its cytotoxic effects on cancerous cells without any harm to normal cells (5,55,56). Recombinant soluble TRAIL induces apoptosis within 4 to 8 h in a number of transformed cell lines derived from leukemia, multiple myeloma, neuroblastoma, and cancers of the colon, lung, breast, prostate, pancreas, kidney, central nervous system, and thyroid. Mice bearing solid tumors, when injected with soluble TRAIL, showed increased tumor cell apoptosis, suppressed tumor progres- sion, and improved survival without any normal-tissue toxicity (11,12,57–62). Admin- istration of TRAIL to mice transplanted with human tumor xenografts derived from colon carcinoma, breast cancer, mammary adenocarcinoma, multiple myeloma, or malignant glioma, exerted marked antitumor activity without systemic toxicity (10,12,63–66).
TRAIL was also shown to inhibit growth of evolving tumors immediately after xenograft implantation, as well as in established tumors. Additionally, agonistic antibodies to DR5, whose binding to the receptor would imitate binding of TRAIL, were shown to induce apoptosis in human astroglioma cells and liver cancer cells (67,68). Moreover, the fact that p53 status does not correlate with TRAIL sensitivity raises an optimistic view of TRAIL as an anticancer agent, as nearly 50% of human tumors show mutation in p53.
As an alternate to administration of soluble TRAIL, adenoviral gene therapy vehicles
for TRAIL have been utilized with promising results both in vitro and in small experimen-
tal animals (69–72). Prolonged survival of nude mice bearing ovarian cancer xenografts
have been reported upon administration of adenoviral vectors harboring the TRAIL gene
(72). Therapeutic efficacy of TRAIL gene therapy has also been demonstrated with colon cancer, prostrate tumors, glioblastoma, breast cancer, and hepatocellular carcinoma (71,73–76). Taken together, these results indicate substantial promise for TRAIL in the treatment of human cancers.
Warning bells were recently heard when normal human hepatocytes, brain cells, and keratinocytes were shown to be sensitive to TRAIL, which suggested a potential for systemic toxicity if TRAIL were to be used for clinical trials (77–79). However, reassess- ment of these results suggests that TRAIL toxicity in hepatocytes and keratinocytes depended on the form and source of the recombinant TRAIL used (80,81). For example, hepatotoxicity was observed with polyhistidine-tagged soluble TRAIL, and keratinocytes were sensitive to both the soluble version of the ligand, which contained a trimerizing leucine zipper, and polyhistidine-tagged TRAIL. However, when non-tagged soluble TRAIL was used, toxicity in hepatocytes and keratinocytes was not observed (80,81).
Furthermore, in preclinical trials in cynomolgus monkeys and chimpanzees, intravenous administration of non-tagged TRAIL was well tolerated, with no harmful symptoms in either laboratory parameters or organ histology (80). Similarly, non-tagged TRAIL was well tolerated by normal human keratinocytes (81). These results rebuild the enthusiasm of clinical oncologists for TRAIL as a potent cancer therapeutic. However, further studies are needed to evaluate toxicity and potential species-specific effects.
TUMOR RESISTANCE TO APOPTOSIS
IN THE DEATH RECEPTOR SIGNALING PATHWAY
A major impediment for the clinical use of TRAIL is that there are a number of tumor cell lines resistant to TRAIL-mediated cell death (Table 1). Although mechanisms under- lying such resistance are not fully understood, there is distinct delineation between resis- tance observed in normal and tumor cells (5,23,55). Several factors have been proposed to impose resistance to TRAIL. For example, relative abundance and access of death and decoy receptors, relative activities of caspase-8 and -10, FLIP, and activity of phosphatidylinositol 3' kinase/Akt pathway ultimately determine sensitivity of cells to TRAIL. Additionally, tissue- and species-specific responses compound the understand- ing of factors involved in TRAIL-mediated apoptosis (55).
Multiple Receptor Interactions for Tumor Proliferation
In the context of multiple receptors for TRAIL, some capable of triggering apoptosis while others abrogate TRAIL activity, resistance could be due to increased levels of DcR1 and DcR2 and decreased levels of proapoptotic DR4 and DR5. However, in the majority of normal and tumor cell lines, no decipherable correlation was observed between different types of TRAIL receptor expression and TRAIL susceptibility (28,60,79,82–85).
Such results suggest that subcellular distribution of death and decoy receptors and their
reorganization upon treatment with TRAIL could play a key role. In melanoma cells,
upon addition of TRAIL, reorganization of death receptors between different sub-cellu-
lar compartments and the cell surface is observed (86,87). Relocation of decoy receptors
DcR1 and DcR2 to the cell surface from the nucleus and down-regulation of cell-surface
expression of DR5 were also observed in the same system (87).
Table 1
Mechanisms of Synergy Between TRAIL and Cytotoxic Agent
1. Upregulation of death receptors by cytotoxic agents
Cytotoxic agent Death receptor upregulated Tumor cell type (reference)
Ara-C DR5 Acute leukemia (85)
Doxorubicin Etoposide
Etoposide DR4 and DR5 Breast carcinoma (128)
Ionizing radiation DR5 Breast carcinoma (113)
Etoposide DR5 Glioma (122)
CDDP
Topotecan DR5 Renal cell carcinoma (114)
Retinoid CD437 DR4 and DR5 Lung and lung cancer (129)
Ionizing radiation DR4 Erythroleukemia (130)
Adriamycin DR5 Multiple myeloma (131)
Etoposide
Adriamycin DR4 and DR5 Osteogenic sarcoma (132)
Cisplatin Etoposide
Doxorubicin DR5 Glioma (133)
cisplatin
2. Modulation of proteins involved in apoptosis by cytotoxic agents Cytotoxic agents
used in conjunction
with TRAIL Targeted apoptotic protein Tumor cell type (reference) Actinomycin D Downregulation of Bcl-xL AIDS–Kaposi’s sarcoma (134) Actinomycin D Downregulation of FLIP Melanoma (28)
5-FU Increased capsase-3 activity Breast carcinoma (58) Doxorubicin
Retinoid CD437 Increased Bid cleavage Lung cancer (129) Sodium butyrate Downregulation of FLIP Colon carinoma (29,135) Actinomycin D Increased caspase-3 activity
Cycloheximide
Cisplatin Activation of caspase-8 Colon carcinoma (117) Doxorubicin
Cisplatin Upregulation of Bax Bladder cancer (59) Carboplatin
Nitroprusside Augmentation by intrinsic Colon carcinoma (136) pathway
5'-aza-2'deoxycytidine Demethylation of caspase-8 Neuroblastoma (107,108) promoter and up-regulation
of caspase-8 continued
2. Modulation of proteins involved in apoptosis by cytotoxic agents (continued) Cytotoxic agents
used in conjunction
with TRAIL Targeted apoptotic protein Tumor cell type (reference) Actinomycin Downregulation of FLIP Pancreatic cancer (137) Smac agonist Bypassing Bcl-3 block Glioma (138)
5-FU Upregulation of Bax and p53 Renal cell carcinoma (139) Doxoruicin Activation of caspase cascade Prostrate cancer (140) Epirubicin
Pirarubicin Amrubicin
Doxorubicin Increased FADD and procaspase-8 Colon carcinoma (141)
5-FU recruitment to DISC
3. Other examples of synergy between TRAIL and cytotoxic agents
Cytotoxic agent used in conjunction with TRAIL Tumor cell type (reference)
Ionizing radiation Acute leukemia (142)
Adriamycin Bladder cancer (59)
Epirubicin Pirarubicin
Proteasome inhibitors Ewing’s sarcoma (143)
Cycloheximide Glioma (144)
Actinomycin D Hepatocellular carcinoma (116)
Doxorubicin Campothecin
Cisplatin Ovarian cancer (112)
Doxorubicin Paclitaxel
Proteasome inhibitors Promonocytic leukemia (145)
Actinomycin D Prostrate cancer (146)
Gemcitabine
Cisplatin Prostrate cancer (123)
Doxorubicin Etoposide
Cycloheximide Thyroid cancer (147)
FLIP
Abundant expression of an inhibitor of death receptor signaling, namely c-FLIP, has
been shown to confer resistance to tumor cells (28,88). Analysis of the expression pattern
of FLIP and relative resistance/susceptibility to TRAIL in melanoma, glioma, and colon
carcinoma revealed that expression of FLIP was highest in cells that were resistant to
TRAIL (28,89,90). Such resistant cells could be converted to TRAIL-susceptible cells
when treated with protein-synthesis inhibitors or chemotherapeutic drugs that interfere
with expression of FLIP (28,91–94). These observations suggest that the balance of
expression of DISC components may play a key role in transduction of the death signal.
Interestingly, injection of cells overexpressing FLIP in mice consistently resulted in tumors, while cells with little or no FLIP were rejected in the majority of mice, suggesting that not only does FLIP make tumors more resistant to TRAIL-mediated cell death, but that it is also involved in the evasion by these tumors from the host immune system (94a).
Thus, understanding the mechanism underlying the action of DISC components and clinical intervention using targeted drug therapy at this early stage of apoptosis is critical for efficacious cancer therapy.
Akt
An equilibrium between anti- and proapoptotic signals could also play a key role in dictating the outcome of an apoptogenic trigger by a death ligand. For example, some prostate cancer cells express constitutively active Akt/protein kinase B due to the loss of lipid phosphatase gene PTEN, a negative regulator of PI-3 kinase (95–97). TRAIL sen- sitivity of these cells was dependent on the level of Akt; cells expressing the highest level of Akt were the most resistant, and such resistance could be reversed by treating with a PI-3 kinase inhibitor such as wortmannin and LY294002 (98–100). Recently, additional examples of a correlation between Akt activity and resistance to TRAIL signaling have been reported in human colon cancer cells, multiple myeloma, thyroid carcinoma, and non-small-cell lung cancer cells (91,101–103). These observations suggest that modula- tion of Akt activity, by genetic or pharmacological intervention, may be important in effective killing of these cancer cells by TRAIL.
Caspase-8
Analysis of the native DISC components suggests that caspase-8 is a key player in early TRAIL-mediated signaling for apoptosis. On the other hand, caspase-10, though recruited to the DISC, is dispensable for induction of apoptosis (3,104,105). However, dendritic cells harboring a mutant caspase-10 are refractory to TRAIL-induced cell death, suggesting that catalytically inactive mutant caspase-10 may act as a nonreleasable sub- strate trap for caspase-8 (104). Alternatively, as observed in certain neuroblastomas, caspase-8 is downregulated by hypermethylation of its promoter, leading to a decreased response to TRAIL-induced cell death (106). However, treatment of neuroblastoma cells with aza-2'-deoxycytidine restores mRNA expression of caspase-8 and TRAIL suscep- tibility (107–110).
COMBINATION THERAPY
In an effort to overcome the fact that many human tumors cells are resistant to TRAIL, the concept of combination therapy was envisaged. This was based on the idea that pretreatment of tumor cells with a radio- or chemotherapeutic agent would sensitize them to TRAIL.
A number of studies have shown cooperation between chemotherapeutic drugs or
radiation and TRAIL in inducing cell death in malignant mesothelioma, ovarian, pros-
trate, bladder, renal, pancreatic, glial, and breast cells (58,59,111–118). The molecular
basis behind such synergy is being actively investigated, and a number of different
mechanisms have been suggested. A list of possible mechanisms of synergy observed between various cytotoxic agents and TRAIL in different tumor cell types has been listed in Table 1.
First, chemotherapeutic drugs or radiation could trigger an apoptotic pathway that may be different than one exploited by TRAIL, to thus transduce a more potent pro-apoptotic signal. For example, Bcl-2 localized to mitochondria or endoplasmic reticulum inhibits apoptosis induced by DNA damage but is unable to confer similar resistance to TRAIL- induced cell death (119) Thus, dual treatment could lead to simultaneous activation of distinct apoptotic pathways, resulting in better killing of tumor cells. However, chemo- therapeutic drugs have diverse cellular targets, which include RNA, DNA, topoisomerase I or II, kinases, microtubules, or the plasma membrane. The mechanism by which these drugs trigger apoptosis remains to be understood. Such knowledge would aid in choosing effective combination therapy to eliminate drug-resistant cells.
DNA damage has been reported to up-regulate DR5 transcription in human cancer cells (113,115,120,121). By monitoring tumor therapy by noninvasive diffusion- weighted MRI, we have previously shown that TRAIL works in concert with radiation to eradicate breast cancer tumors, and that such synergy is mediated by up-regulation of the DR5 receptor (113). Similar synergy between DNA-damaging drugs like cisplatin (CDDP) or etoposide and TRAIL was also observed in gliomas (122,123). Using such combination therapy, normal tissue toxicity of the DNA-damaging drugs could be over- come using sublethal doses, which do not kill the normal cells but cause up-regulation of the DR5 in tumor cells. Addition of TRAIL to such tumors would systemically elimi- nate them. However, DR5 upregulation by DNA-damaging drugs was observed to be dependent on the tumor suppressor gene p53, thus limiting the use of such combination therapy, as the majority of cancer cells display p53 mutations (113,121,124). On the contrary, recent studies demarcate the link between p53 and upregulation of DR5 expres- sion in a number of tumor cell lines (125). The other TRAIL death receptor, DR4, was recently shown to be upregulated upon DNA damage (126). Interestingly, some reports indicate that such TRAIL and DNA-damaging agent synergy could be independent of DR4 and DR5 upregulation, suggesting that other mechanisms may prevail for a con- certed effect (127). Taken together, the combination therapy using TRAIL and DNA- damaging agents may be a safe therapeutic strategy for human malignancies, including TRAIL-resistant cancers.
ACKNOWLEDGMENTS
We thank Laura Griffin and Bharathi Laxman for critical reading of the manuscript.
This work was supported by NIH/NCI P50CA01014 (BDR and AR) and NIH/NCI P01CA85878 (BDF and AR).
REFERENCES
1. Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251–306.
2. Strasser A, O’Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000;69:217–245.
3. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002;9:459–470.
4. Kaufmann SH, Gores GJ. Apoptosis in cancer: cause and cure. Bioessays 2000;22:1007–1017.
5. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420–430.
6. Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000;1:469–474.
7. Krammer PH. CD95’s deadly mission in the immune system. Nature 2000;407:789–795.
8. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673–682.
9. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo- 2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687–2690.
10. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255–260.
11. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand.
J Clin Invest 1999;104:155–162.
12. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor–related apoptosis- inducing ligand in vivo. Nat Med 1999;5:157–163.
13. Hymowitz SG, O’Connell MP, Ultsch MH, et al. A unique zinc-binding site revealed by a high-resolu- tion X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000;39:633–640.
14. Hymowitz SG, Christinger HW, Fuh G, et al. Triggering cell death: the crystal structure of Apo2L/
TRAIL in a complex with death receptor 5. Mol Cell 1999;4:563–571.
15. Bodmer JL, Meier P, Tschopp J, Schneider P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem 2000;275:20,632–20,637.
16. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818–821.
17. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain- containing receptor for TRAIL. Science 1997;277:815–818.
18. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. Embo J 1997;16:5386–5397.
19. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incom- plete death domain. Immunity 1997;7:813–820.
20. Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186:1165–1170.
21. Pan G, O’Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111–113.
22. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
J Biol Chem 1998;273:14,363–14,367.
23. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277–288.
24. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated pro- teins form a death-inducing signaling complex (DISC) with the receptor. Embo J 1995;14:5579–5588.
25. Kischkel FC, Lawrence DA, Tinel A, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001;276:46,639–46,646.
26. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817–827.
27. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001;21:8247–8254.
28. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161:2833–2840.
29. Hernandez A, Wang QD, Schwartz SA, Evers BM. Sensitization of human colon cancer cells to TRAIL- mediated apoptosis. J Gastrointest Surg 2001;5:56–65.
30. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309–1312.
31. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis.
Genes Dev 1999;13:1899–1911.
32. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43–53.
33. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c- dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33–42.
34. Zou H, Li Y, Liu X, Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999;274:11,549–11,556.
35. Ekert PG, Silke J, Hawkins CJ, Verhagen AM, Vaux DL. DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9. J Cell Biol 2001;152:483–490.
36. Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 2001;7:95–106.
37. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 2001;20:1063–1075.
38. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000;7:1166–1173.
39. El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001;8:1066–1075.
40. LeBlanc H, Lawrence D, Varfolomeev E, et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002;8:274–281.
41. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002;168:1356–1361.
42. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor–related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195:161–169.
43. Johnsen AC, Haux J, Steinkjer B, et al. Regulation of APO-2 ligand/trail expression in NK cells- involvement in NK cell-mediated cytotoxicity. Cytokine 1999;11:664–672.
44. Jeremias I, Herr I, Boehler T, Debatin KM. TRAIL/Apo-2-ligand-induced apoptosis in human T cells.
Eur J Immunol 1998;28:143–152.
45. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1998;161:2195–2200.
46. Kayagaki N, Yamaguchi N, Nakayama M, et al. Expression and function of TNF-related apoptosis- inducing ligand on murine activated NK cells. J Immunol 1999;163:1906–1913.
47. Kayagaki N, Yamaguchi N, Nakayama M, et al. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999;162:2639–2647.
48. Martinez-Lorenzo MJ, Alava MA, Gamen S, et al. Involvement of APO2 ligand/TRAIL in activation- induced death of Jurkat and human peripheral blood T cells. Eur J Immunol 1998;28:2714–2725.
49. Mariani SM, Krammer PH. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells.
Eur J Immunol 1998;28:1492–1498.
50. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999;189:
1343–1354.
51. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells:
A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999;189:1451–1460.
52. Chen Q, Gong B, Mahmoud-Ahmed AS, et al. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 2001;98:2183–2192.
53. Clarke P, Meintzer SM, Widmann C, Johnson GL, Tyler KL. Reovirus infection activates JNK and the JNK-dependent transcription factor c-Jun. J Virol 2001;75:11,275–11,283.
54. Secchiero P, Mirandola P, Zella D, et al. Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modu- lation in CD4(+) T cells. Blood 2001;98:2474–2481.
55. Held J, Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat 2001;4:243–252.
56. Fricker J. On the TRAIL to a new cancer therapy. Mol Med Today 1999;5:374.
57. Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett 1998;427:124–128.
58. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL- induced apoptosis in breast cell lines. Cancer Res 1999;59:734–741.
59. Mizutani Y, Nakao M, Ogawa O, Yoshida O, Bonavida B, Miki T. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol 2001;165:263–270.
60. Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Ewing’s sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Cancer Res 2001;61:2704–2712.
61. Yu R, Mandlekar S, Ruben S, Ni J, Kong AN. Tumor necrosis factor-related apoptosis-inducing ligand- mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res 2000;60:2384–2389.
62. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999;13:1817–1824.
63. Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacoki- netics, and safety. J Pharmacol Exp Ther 2001;299:31–38.
64. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795–804.
65. Roth W, Isenmann S, Naumann U, et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999;265:479–483.
66. Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001;7:1362–1369.
67. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7:954–960.
68. Choi C, Kutsch O, Park J, Zhou T, Seol DW, Benveniste EN. Tumor necrosis factor–related apoptosis- inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells. Mol Cell Biol 2002;22:724–736.
69. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000;165:2886–2894.
70. Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001;61:3330–3338.
71. Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 2001;4:257–266.
72. Huang X, Lin T, Gu J, et al. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther 2002;9:1379–1386.
73. Norris JS, Hyer ML, Voelkel-Johnson C, Lowe SL, Rubinchik S, Dong JY. The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther 2001;1:123–136.
74. Lee J, Hampl M, Albert P, Fine HA. Antitumor activity and prolonged expression from a TRAIL- expressing adenoviral vector. Neoplasia 2002;4:312–323.
75. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002;9:164–172.
76. Yamashita Y, Shimada M, Tanaka S, Okamamoto M, Miyazaki J, Sugimachi K. Electroporation-me- diated tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)/Apo2L gene therapy for hepatocellular carcinoma. Hum Gene Ther 2002;13:275–286.
77. Nitsch R, Bechmann I, Deisz RA, et al. Human brain-cell death induced by tumour-necrosis-factor- related apoptosis-inducing ligand (TRAIL). Lancet 2000;356:827–828.
78. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564–567.
79. Leverkus M, Neumann M, Mengling T, et al. Regulation of tumor necrosis factor-related apoptosis- inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000;60:
553–559.
80. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/
TRAIL versions. Nat Med 2001;7:383–385.
81. Qin J, Chaturvedi V, Bonish B, Nickoloff BJ. Avoiding premature apoptosis of normal epidermal cells.
Nat Med 2001;7:385–386.
82. Wuchter C, Krappmann D, Cai Z, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity.
Leukemia 2001;15:921–928.
83. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis- inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999;59:2747–2753.
84. Griffith TS, Rauch CT, Smolak PJ, et al. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999;162:2597–2605.
85. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000;96:3900–3906.
86. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000;482:193–199.
87. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000;164:3961–3970.
88. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190–195.
89. Xiao C, Yang BF, Asadi N, Beguinot F, Hao C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 2002;277:25,020–25,025.
90. Bin L, Li X, Xu LG, Shu HB. The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett 2002;510:37–40.
91. Poulaki V, Mitsiades CS, Kotoula V, et al. Regulation of Apo2L/tumor necrosis factor-related apoptosis- inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol 2002;161:643–654.
92. Shin EC, Seong YR, Kim CH, et al. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 2002;34:114–122.
93. Elnemr A, Ohta T, Yachie A, et al. Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int J Oncol 2001;18:311–316.
94. Tepper CG, Seldin MF. Modulation of caspase-8 and FLICE-inhibitory protein expression as a poten- tial mechanism of Epstein-Barr virus tumorigenesis in Burkitt’s lymphoma. Blood 1999;94:1727–737.
94a. Djerbi M, Screpanti V, Bogen B, Catrina A, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumour progression factors. J Exp Med 1999;190:1025–1032.
95. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943–1947.
96. Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998;95:5246–5250.
97. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998;58:2720–2723.
98. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001;
276:10,767–10,774.
99. Chen X, Thakkar H, Tyan F, et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001;20:6073–6083.
100. Thakkar H, Chen X, Tyan F, et al. Pro-survival function of Akt/protein kinase B in prostate cancer cells:
relationship with trail resistance. J Biol Chem 2001;276:38,361–38,369.
101. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21:5673–5683.
102. Wang Q, Wang X, Hernandez A, Hellmich MR, Gatalica Z, Evers BM. Regulation of trail expression by the PI3-KINASE/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem 2002;277:
36,602–36,610.
103. Kandasamy K, Srivastava RK. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 2002;62:4929–4937.
104. Wang J, Zheng L, Lobito A, et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999;98:47–58.
105. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-depen- dent manner but can not functionally substitute caspase-8. Embo J 2002;21:4520–4530.
106. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6:529–535.
107. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N. Loss of caspase- 8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necro- sis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000;60:4315–4319.
108. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865–5877.
109. Eggert A, Grotzer MA, Zuzak TJ, et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expres- sion. Cancer Res 2001;61:1314–1319.
110. Zuzak TJ, Steinhoff DF, Sutton LN, Phillips PC, Eggert A, Grotzer MA. Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. Eur J Cancer 2002;38:83–91.
111. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand’s antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999;59:6153–6158.
112. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001;81:380–390.
113. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000;97:1754–1759.
114. Dejosez M, Ramp U, Mahotka C, et al. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ 2000;7:1127–1136.
115. Gong B, Almasan A. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res 2000;60:5754–5760.
116. Yamanaka T, Shiraki K, Sugimoto K, et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000;32:482–490.
117. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001;61:1645–1651.
118. Liu W, Bodle E, Chen JY, Gao M, Rosen GD, Broaddus VC. Tumor necrosis factor–related apoptosis- inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol 2001;25:111–118.
119. Rudner J, Lepple-Wienhues A, Budach W, et al. Wild-type, mitochondrial and ER-restricted Bcl-2 inhibit DNA damage-induced apoptosis but do not affect death receptor-induced apoptosis. J Cell Sci 2001;114:4161–4172.
120. Sheikh MS, Burns TF, Huang Y, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998;58:1593–1598.
121. Wu GS, Burns TF, McDonald ER, 3rd, et al. KILLER/DR5 is a DNA damage–inducible p53-regulated death receptor gene. Nat Genet 1997;17:141–143.
122. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expres- sion by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor–related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000;60:847–853.
123. Munshi A, McDonnell TJ, Meyn RE. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol 2002;50:46–52.
124. Wu GS, Kim K, el-Deiry WS. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol 2000;465:143–151.
125. Meng RD, El-Deiry WS. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res 2001;262:154–169.
126. Guan B, Yue P, Clayman GL, Sun SY. Evidence that the death receptor DR4 is a DNA damage- inducible, p53-regulated gene. J Cell Physiol 2001;188:98–105.
127. Rohn TA, Wagenknecht B, Roth W, et al. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Oncogene 2001;20:4128–4137.
128. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000;20:205–212.
129. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2- naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000;60:7149–7155.
130. Di Pietro R, Secchiero P, Rana R, et al. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 2001;97:2596–2603.
131. Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-induc- ing ligand-mediated (TRAIL) apoptosis. Clin Cancer Res 2001;7:3874–3883.
132. Evdokiou A, Bouralexis S, Atkins GJ, et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002;99:491–504.
133. Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K. A mechanism of resis- tance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents. Br J Cancer 2003;88:298–306.
134. Mori S, Murakami-Mori K, Jewett A, Nakamura S, Bonavida B. Resistance of AIDS-associated Kaposi’s sarcoma cells to Fas-mediated apoptosis. Cancer Res 1996;56:1874–1879.
135. Hernandez A, Thomas R, Smith F, et al. Butyrate sensitizes human colon cancer cells to TRAIL- mediated apoptosis. Surgery 2001;130:265–272.
136. Lee YJ, Lee KH, Kim HR, et al. Sodium nitroprusside enhances TRAIL-induced apoptosis via a mito- chondria-dependent pathway in human colorectal carcinoma CX-1 cells. Oncogene 2001;20:1476–1485.
137. Matsuzaki H, Schmied BM, Ulrich A, et al. Combination of tumor necrosis factor–related apoptosis- inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pan- creatic cancer cells. Clin Cancer Res 2001;7:407–414.
138. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:808–815.
139. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 2002;38:167–176.
140. Wu XX, Kakehi Y, Mizutani Y, et al. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 2002;20:949–954.
141. Lacour S, Micheau O, Hammann A, et al. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003;22:1807–1816.
142. Belka C, Schmid B, Marini P, et al. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 2001;20:2190–2196.
143. Van Valen F, Fulda S, Truckenbrod B, et al. Apoptotic responsiveness of the Ewing’s sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int J Cancer 2000;88:252–259.
144. Wu M, Das A, Tan Y, Zhu C, Cui T, Wong MC. Induction of apoptosis in glioma cell lines by TRAIL/
Apo-2l. J Neurosci Res 2000;61:464–470.
145. Mlynarczuk I, Hoser G, Grzela T, et al. Augmented pro-apoptotic effects of TRAIL and proteasome inhibitor in human promonocytic leukemic U937 cells. Anticancer Res 2001;21:1237–1240.
146. Zisman A, Ng CP, Pantuck AJ, Bonavida B, Belldegrun AS. Actinomycin D and gemcitabine syner- gistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis.
J Immunother 2001;24:459–471.
147. Ahmad M, Shi Y. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic interven- tion. Oncogene 2000;19:3363–3371.
